CN1259912C - 用于治疗升高的血压的西酞普兰 - Google Patents
用于治疗升高的血压的西酞普兰 Download PDFInfo
- Publication number
- CN1259912C CN1259912C CNB038012936A CN03801293A CN1259912C CN 1259912 C CN1259912 C CN 1259912C CN B038012936 A CNB038012936 A CN B038012936A CN 03801293 A CN03801293 A CN 03801293A CN 1259912 C CN1259912 C CN 1259912C
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- citalopram
- application
- pharmaceutical composition
- elevated blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960001653 citalopram Drugs 0.000 title claims abstract description 62
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title claims abstract description 61
- 230000036772 blood pressure Effects 0.000 title claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000010606 normalization Methods 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 206010020772 Hypertension Diseases 0.000 claims description 28
- 208000019906 panic disease Diseases 0.000 claims description 20
- 239000002220 antihypertensive agent Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 8
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 7
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
- 229960002237 metoprolol Drugs 0.000 claims description 4
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
- 229960001455 quinapril Drugs 0.000 claims description 4
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 4
- 229960003401 ramipril Drugs 0.000 claims description 4
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 4
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 3
- 229940123749 Imidazoline receptor agonist Drugs 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 3
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 229940097320 beta blocking agent Drugs 0.000 claims description 3
- 239000000480 calcium channel blocker Substances 0.000 claims description 3
- -1 direct vasodilation Substances 0.000 claims description 3
- 229960004341 escitalopram Drugs 0.000 claims description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 claims description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 claims description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 claims description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
- CBYQELOJKLRUAG-UHFFFAOYSA-N COC=1C(=C(NC=1)OC)OC Chemical class COC=1C(=C(NC=1)OC)OC CBYQELOJKLRUAG-UHFFFAOYSA-N 0.000 claims description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 claims description 2
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical group COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 claims description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 2
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 claims description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
- ZUMPSVPHCDJCMD-UHFFFAOYSA-N abitesartan Chemical compound C1CCCC1(C(O)=O)CN(C(=O)CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ZUMPSVPHCDJCMD-UHFFFAOYSA-N 0.000 claims description 2
- 229950010933 abitesartan Drugs 0.000 claims description 2
- 229960002122 acebutolol Drugs 0.000 claims description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical group CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000528 amlodipine Drugs 0.000 claims description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 229960004324 betaxolol Drugs 0.000 claims description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002781 bisoprolol Drugs 0.000 claims description 2
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 2
- 229950005341 bucindolol Drugs 0.000 claims description 2
- 229960000932 candesartan Drugs 0.000 claims description 2
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229960001222 carteolol Drugs 0.000 claims description 2
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004195 carvedilol Drugs 0.000 claims description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims description 2
- 229960002896 clonidine Drugs 0.000 claims description 2
- 229960004042 diazoxide Drugs 0.000 claims description 2
- 229960004166 diltiazem Drugs 0.000 claims description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001389 doxazosin Drugs 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- 229960003580 felodipine Drugs 0.000 claims description 2
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002724 fenoldopam Drugs 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 229960004553 guanabenz Drugs 0.000 claims description 2
- 229960002048 guanfacine Drugs 0.000 claims description 2
- 229960002474 hydralazine Drugs 0.000 claims description 2
- 229960004427 isradipine Drugs 0.000 claims description 2
- 229960001632 labetalol Drugs 0.000 claims description 2
- 229960004340 lacidipine Drugs 0.000 claims description 2
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical group CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- 229960003938 moxonidine Drugs 0.000 claims description 2
- 229960004255 nadolol Drugs 0.000 claims description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 2
- 229960001783 nicardipine Drugs 0.000 claims description 2
- 229960001597 nifedipine Drugs 0.000 claims description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 229960000227 nisoldipine Drugs 0.000 claims description 2
- 229960002035 penbutolol Drugs 0.000 claims description 2
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 229960003418 phenoxybenzamine Drugs 0.000 claims description 2
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001999 phentolamine Drugs 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims description 2
- 229960005141 piperazine Drugs 0.000 claims description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001289 prazosin Drugs 0.000 claims description 2
- 229960003712 propranolol Drugs 0.000 claims description 2
- 229960000764 rilmenidine Drugs 0.000 claims description 2
- 229960005187 telmisartan Drugs 0.000 claims description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960001693 terazosin Drugs 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 229960002051 trandolapril Drugs 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
- 229960001722 verapamil Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000019901 Anxiety disease Diseases 0.000 description 12
- 208000017194 Affective disease Diseases 0.000 description 11
- 208000019022 Mood disease Diseases 0.000 description 11
- 206010049079 Labile hypertension Diseases 0.000 description 10
- 230000036506 anxiety Effects 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 208000008811 Agoraphobia Diseases 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 229940047493 celexa Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 206010054089 Depressive symptom Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- ANJLMAHUPYCFQY-UHFFFAOYSA-N 4-phenyl-1h-benzimidazole-2-sulfonic acid Chemical class C=12NC(S(=O)(=O)O)=NC2=CC=CC=1C1=CC=CC=C1 ANJLMAHUPYCFQY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940066008 citalopram 20 mg Drugs 0.000 description 1
- 230000035601 cold sensitivity Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940071979 sertraline 100 mg Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dental Preparations (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及西酞普兰或其可药用盐在制备适于治疗升高的(高)血压、使血压正常化或降低升高的血压和/或预防升高的血压的药物组合物中的应用。
Description
发明领域
本发明涉及西酞普兰(citalopram)的新应用。
发明技术背景
已知1-(3-二甲氨基-丙基)-1-(4-氟-苯基)-1，3-二氢-5-异苯并呋喃-腈(INN西酞普兰)是众所周知的抗抑郁药物活性成分(DE 2,657,103)。在EP 346,066中描述了光学活性的(S)-西酞普兰也具有抗抑郁活性。
已知若干用于制备西酞普兰的合成方法(WO 98/19512和WO98/19513)。
从包含西酞普兰的产品信息宣传品(例如“Celexa Side EffectsCelexa Drug Interactions Citalopram-Rx List Monographs”)中得知，在用西酞普兰治疗抑郁的过程中，血压过低作为不合需要的副作用会发生。
然而，这并不意味着西酞普兰被宣称作为使高血压患者血压正常化的产品。第一：上面提及的参考文件没有涉及高血压患者。第二：它公开了“虽然在用CelexaTM进行治疗的过程中发生了报导的病例，但是由CelexaTM引起的所述副作用不是必然的(“CelexaTM”是包含西酞普兰的产品的商标)”。第三：事实是高血压(即与低血压相反)也被作为不合需要的副作用提出，强烈地支持了此陈述，即参考文献没有包含明显的由西酞普兰引起低血压的教导。第四：不合需要的血压过低的诱导不是血压正常化效应，因为低血压本身是不正常的血压。基于上述理由，所引用的参考文献没有教导或公开应用西酞普兰来分别治疗高血压、使血压正常化或降低升高的血压。
前面所述的参考文献也涉及信息宣传品“SEROPRAM product，active ingredient CITALOPRAM”，其中提及作为不合需要的副作用的体位性低血压的情况。
发明概述
本发明的目标是研究西酞普兰或其可药用盐的新应用。
在本发明的帮助下，上述目标以出乎意料的方式被解决了。
本发明涉及西酞普兰或其可药用盐在制备适于治疗升高的(高)血压、使血压正常化或降低升高的血压和/或预防血压升高的药物组合物中的应用。本发明还涉及制备如下用途的药物组合物：适于治疗和/或预防惊恐性障碍患者的升高的血压、治疗和/或预防原发性升高的血压、预防和/或治疗中风。
发明详细说明
在本专利说明书中使用的术语的定义如下：
术语“可药用盐”涉及与可药用无机酸或有机酸形成的盐。这些盐是盐酸盐、氢溴酸盐、硫酸盐、磷酸盐、硝酸盐、醋酸盐、酒石酸盐、马来酸盐、富马酸盐、乳酸盐、马来酸盐、苯基磺酸盐等等。
术语“高血压”指血压为180/110Hgmm或更高值。
术语“正常血压”指血压为130/80Hgmm±10Hgmm。
可以使用西酞普兰的外消旋化合物或光学活性形式，例如(S)-西酞普兰。
西酞普兰具有众多超过已知抗高血压剂的优点。通常，在临床实践中使用抗高血压剂不能达到血压的正常化，部分是因为血压的波动，部分是由于血压降到了低于正常水平。大多数已知的抗高血压剂的缺点是诱导失眠、疲劳、特别是在清晨的激惹现象、注意力不集中、记忆和心情问题、运动减少。另一方面，西酞普兰不引起焦虑和情感障碍，其主要的适应症降低恰恰是治疗了这种障碍。
西酞普兰可以被极好地应用于使血压正常化。在用通常使用的抗高血压剂治疗的过程中很常见的是，先前是正常血压或低血压的并从抑郁或焦虑性障碍中康复的患者在数月或数年后变为了高血压。在这些病例中，用西酞普兰替代迄今使用的抗高血压剂除了使血压正常化外，还消除了情感性和焦虑性疾病。
按照本发明的优选的具体实施方式，西酞普兰或其可药用盐被用来治疗和/或预防不稳定性血压升高。
按照本发明进一步优选的具体实施方式，西酞普兰或其可药用盐被用来治疗和/或预防在惊恐性障碍患者身上发生的血压升高。
不稳定性高血压不仅仅是20岁左右的年轻一代所特有的。实践证明，不稳定性高血压在儿童期至老年期都存在，并且经常呈现惊恐性障碍的最初迹象。然而，这只是外表上的观察。广泛的既往病史揭示，情感障碍或惊恐性障碍，有时仅是一、两次零星的惊恐发作，在老龄患者的医学史上已有发生。
基于上述理由，西酞普兰尤其适用于并且优选来治疗上述类型的升高的血压。
伴随惊恐性障碍发生的不稳定性高血压在经过一段时间后会转变成严重的固定高血压。已经出乎意料地发现，西酞普兰在治疗上述疾病方面是有用的，也就是使同时伴随惊恐性障碍所有症状的不稳定性血压正常化，包括惊恐性发作、期待焦虑、广场恐怖、和半数与抑郁相关的惊恐性障碍病例。
在上述疾病的情况下，高血压的发生指示施用西酞普兰的必要性。
按照本发明另外优选的具体实施方式，西酞普兰或其可药用盐被用来治疗和/或预防原发性升高的血压。
80％血压升高的患者是原发性高血压。假定术语“原发性”是指在大多数病例中(相关的高血压小组)对西酞普兰(应激性)完全响应。
按照本发明另外优选的具体实施方式，西酞普兰或其可药用盐被用来预防和/或治疗中风。
已知众多中风患者属于高血压患者。中风是世界范围内严重的有害因素。全世界约有五千五百万人患有不稳定性高血压，但是从不稳定性高血压起源的固定高血压患者的数目则要高若干倍。
在匈牙利，1979年有170,000名年龄低于40岁的患者患有中风并死亡。
西酞普兰能被用来长期单独或是与其它抗高血压剂结合治疗高血压。
西酞普兰在单独治疗中已经改善了温和的或中度的高血压。在更多严重的病例中，西酞普兰也显示明显的抗高血压作用，即另外的抗高血压剂可以较低的剂量给药。相应地，在每天的医疗实践中，西酞普兰使血压正常化。
按照本发明另外的优选具体实施方式，制备药物组合物，其包含西酞普兰或它的可药用盐以及另外的抗高血压剂。为此，例如可以使用如下的抗高血压剂：具有中枢性作用的抗高血压剂，优选甲基多巴、氯压定、胍法新、氯压胍；β-阻断剂，优选醋丁酰心安、氨酰心安、倍他洛尔、比索洛尔、喹酮心安、心得安、美多洛尔、纳多洛尔、喷布洛尔、吲哚洛尔、噻吗洛尔、布新洛尔、拉贝洛尔、卡维洛尔、nevibolol；α-阻断剂，优选哌唑嗪、特拉唑嗪、多沙唑嗪、三甲氧唑嗪、酚苄明、酚妥拉明；直接血管扩张剂，优选肼苯哒嗪、长压定、氯甲苯噻嗪、非诺多巴；钙通道阻滞剂，优选维拉帕米、地尔硫、硝苯地平、尼莫地平、费乐地平、尼卡地平、伊拉地平、氨氯地平、尼索地平、拉西地平；ACE-抑制剂，优选卡托普利、依那普利、赖诺普利、喹那普利、雷米普利、贝那普利、福森普利、甲硫普利、喹那普利、哌道普利、雷米普利、群多普利；血管紧张素II受体拮抗剂，优选氯沙坦、坎地沙坦、阿比沙坦、缬沙坦、替米沙坦、依普罗沙坦；咪唑啉受体激动剂，优选莫索尼定、利美尼定。上述列举只是作为范例的目的，而不构成限制。
本发明的抗高血压药物组合物优选除包含西酞普兰或其可药用盐外还包含至少一种可药用惰性载体和/或辅剂。
按照本发明制备的包含西酞普兰的抗高血压药物组合物优选口服或肠胃外给药。用于口服给药的，例如片剂、包衣片剂、硬或软明胶胶囊。也可以使用糖衣丸、溶液剂、混悬剂或乳剂。胃肠外药物组合物例如可以是静脉内、肌内或腹膜内注射液。
口服给药的固体药物组合物除包含活性成分外还包含常用的药用赋形剂。出于此目的，例如可以使用粘合剂(例如明胶、山梨醇和/或聚乙烯吡咯烷酮)，载体(例如乳糖、葡萄糖、淀粉和/或磷酸钙)，压片辅剂(例如硬脂酸镁、滑石粉和/或二氧化硅)和/或润湿剂(例如十二烷基硫酸钠)。
口服给药的液体药物组合物例如可以是溶液剂、混悬剂或乳剂。这种组合物可以包含混悬剂(例如明胶和/或羧甲基纤维素)，乳化剂(例如失水山梨糖醇单油酸酯)，溶剂(例如水、油、甘油、聚乙二醇和/或乙醇)和/或防腐剂(例如甲基-p-羟基-苯甲酸酯)。
肠胃外给药的药物组合物优选是活性成分与水或等渗氯化钠溶液形成的无菌溶液。
用作抗高血压剂的西酞普兰的每日剂量优选为约0.01mg/kg体重-约2mg/kg体重，尤其为约0.07mg/kg体重-1mg/kg体重。西酞普兰的初始剂量优选是约5mg/天，在其后的数月，稳定剂量是约20-60mg/天。(S)-西酞普兰的剂量大约是上述值的一半。
在口服治疗的情况下，以输注形式给西酞普兰可能是必须的(初始“负荷”剂量)。
按照本发明的另一方面，其提供了治疗升高的(高)血压、使血压正常化或降低升高的血压和/或预防血压升高的方法，包括向需要此治疗的患者施用药学有效量的西酞普兰和/或其可药用盐。
按照本发明优选的具体实施方式，所述治疗方法被用于治疗患不稳定性升高的血压的患者。
按照本发明另一优选的具体实施方式，所述治疗方法被用来治疗患不稳定性血压合并惊恐性障碍的患者。
按照本发明的另一优选的具体实施方式，所述治疗方法被用来治疗患原发性升高的血压的患者。
按照本发明另一优选的具体实施方式，所述治疗方法被用来治疗患中风或易患中风的患者。
通过下面的试验来证明西酞普兰的抗高血压作用。
I.研究
西酞普兰抗高血压作用验证
254名患者参与此研究。所有患者都有高血压。在此高血压组中，120名患者患有惊恐性障碍和广场恐怖，70名患者患有惊恐性障碍合并广场恐怖及抑郁，64名患者患有惊恐性障碍合并广场恐怖及社交恐怖症和/或合并强制性障碍(OCD)。
在第一个星期以5mg/天的剂量给患者施用西酞普兰，在第二个星期10mg/天，在第三和第四个星期20mg/天。
经过4星期治疗，170名患者(67％)完全康复。这些患者血压正常，焦虑性和情感性障碍症状完全消失。
继续以20mg/天的口服剂量用西酞普兰治疗剩余的84名患者。在所述84名患者中，64名患者另外用美多洛尔以2×50mg/天的剂量口服治疗3个星期，20名患者以2×12.5mg/天的剂量给予卡托普利。6星期后获得完全康复，患者血压正常，焦虑性和情感性障碍症状完全消失。
治疗的结果是患不稳定性高血压的患者康复。
上述结果清楚地显示西酞普兰使升高的血压复原，使不稳定性高血压正常化，恢复患者的正常血压状态并另外治愈高血压患者的各种焦虑和抑郁症状。
II.研究
预先用抗抑郁药治疗的不稳定性高血压患者的研究
参予此研究的13名不稳定性高血压患者还患有各种焦虑性障碍和抑郁症。这些患者中3名患有惊恐性障碍，1名患有强制性障碍，9名患有惊恐性障碍合并抑郁。在用下面的抗抑郁药治疗初期，这些患者血压正常。
口服帕罗西丁40mg/天、或舍曲林100mg/天、或氟西汀20mg/天、或三氟戊肟胺150mg/天来治疗患者。在6个月后60％的患者，在12-30个月后40％的患者，除他们的精神病状态恢复正常以外，变成了高血压。
此后用西酞普兰替代上述提及的抗抑郁药。在第一个星期西酞普兰的口服剂量是5mg/天，在第二个星期是10mg/天，在第三个星期是20mg/天。出乎意料地，在治疗结束时，患者变得血压正常。
上述试验结果证明，与参考的抗抑郁剂相反，西酞普兰能够使伴随焦虑和情感性障碍出现的不稳定性高血压正常化。从上述出乎意料的结果清楚地得出，强烈建议开始用西酞普兰来治疗患高血压的焦虑和抑郁患者。
III研究
患有高血压但是无焦虑或抑郁症的患者的研究
在此试验中，有102名高血压患者参与，他们自述有下列症状：攻击样头疼，眩晕，颤抖，出汗，流汗，惧怕死亡，对热和冷敏感及胃肠道疾病。患者认为他们的疾病是惊恐发作的结果，但是这没有以明确的方式得到他们的精神病学既往病史的支持。
在第一个星期，以5mg/天的剂量口服西酞普兰来治疗患者，在第二个星期10mg/天，在第三个星期20mg/天。在三个星期的治疗后，47名患者(46％)康复并变得血压正常。
对于55名无反应的患者，除给予西酞普兰20mg/天以外，40名患者(39％)以100mg/天的口服剂量给美多洛尔，15名患者(15％)以2×12.5mg/天的剂量给卡托普利。在六个星期的治疗后，获得完全康复，并且患者变得血压正常。
上述结果充分显示西酞普兰使高血压正常化，并且也消除了由高血压诱导的惊恐样症状。在这些病例中也强烈建议开始用西酞普兰来治疗。
因此，西酞普兰适合于单独治疗或结合治疗伴随非情感障碍发生的高血压。
IV研究
患惊恐性障碍和/或情感障碍的患者的研究，他们的病例报告包含至少一次高血压发作
25名患有惊恐性障碍和/或情感障碍的患者参与了此项研究。在这些患者的医疗历史中显示有至少一次高血压发作。在第一个星期，以5mg/天的剂量让患者口服西酞普兰，在第二个星期10mg/天，在第三个星期20mg/天。患者完全响应治疗，惊恐性障碍和情感障碍的综合症状彻底停止并且血压维持在正常范围。
上述结果显示，对于患有惊恐性障碍和/或情感障碍且他们的病例记录包含至少一次高血压发作的患者，西酞普兰是极好的选择。即高血压发作可以被认为是必须使用西酞普兰的生物学标志。
V研究
父母患有高血压或中风的抑郁症患者研究
患有焦虑或情感障碍的患者参与此研究，他们父母中的至少一位患有高血压或中风。已经发现，在用西酞普兰以上面公开的口服剂量治疗患者后，在较长的时期内血压维持正常，并且焦虑和抑郁症状也消失。利用任何其它抗抑郁药进行的治疗都不能产生完全的响应。因此，利用西酞普兰治疗上述组的患者是高度优选的。
Claims (11)
1.西酞普兰或其可药用盐在制备适于治疗升高的血压、使血压正常化或降低血压和/或预防升高的血压的药物组合物中的应用。
2.根据权利要求1的应用，制备适于治疗和/或预防不稳定性升高的血压的药物组合物。
3.根据权利要求1或2的应用，制备适于治疗和/或预防惊恐性障碍患者的升高的血压的药物组合物。
4.根据权利要求1的应用，制备适于治疗和/或预防原发性升高的血压的药物组合物。
5.根据权利要求1的应用，制备适于预防和/或治疗中风的药物组合物。
6.根据权利要求1或2的应用，其中使用外消旋西酞普兰。
7.根据权利要求1或2的应用，其中使用(S)-西酞普兰。
8.根据权利要求1或2的应用，其中将西酞普兰或其可药用盐与另外的抗高血压剂一起使用。
9.根据权利要求8的应用，其中使用至少一种下述的抗高血压剂：具有中枢性作用的抗高血压剂、β-阻断剂、α-阻断剂、直接血管扩张剂、钙通道阻滞剂、ACE-抑制剂、血管紧张素II受体拮抗剂、咪唑啉受体激动剂。
10.根据权利要求9的应用，其中所述具有中枢性作用的抗血压剂选自：甲基多巴、氯压定、胍法新或氯压胍；所述β-阻断剂选自醋丁酰心安、氨酰心安、倍他洛尔、比索洛尔、喹酮心安、心得安、美多洛尔、纳多洛尔、喷布洛尔、吲哚洛尔、噻吗洛尔、布新洛尔、拉贝洛尔、卡维洛尔或nevibolol；所述α-阻断剂选自哌唑嗪、特拉唑嗪、多沙唑嗪、三甲氧唑嗪、酚苄明或酚妥拉明；所述直接血管扩张剂选自肼苯哒嗪、长压定、氯甲苯噻嗪或非诺多巴；所述钙通道阻滞剂选自维拉帕米、地尔硫、硝苯地平、尼莫地平、费乐地平、尼卡地平、伊拉地平、氨氯地平、尼索地平或拉西地平；所述ACE-抑制剂选自卡托普利、依那普利、赖诺普利、喹那普利、雷米普利、贝那普利、福森普利、甲硫普利、喹那普利、哌道普利、雷米普利或群多普利；所述血管紧张素II受体拮抗剂选自氯沙坦、坎地沙坦、阿比沙坦、缬沙坦、替米沙坦或依普罗沙坦；所述咪唑啉受体激动剂选自莫索尼定或利美尼定。
11.根据权利要求1或2的应用，其中制备包含至少一种可药用惰性载体和/或辅剂的药物组合物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP0200980 | 2002-03-14 | ||
| HU0200980A HU0200980D0 (zh) | 2002-03-14 | 2002-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1568183A CN1568183A (zh) | 2005-01-19 |
| CN1259912C true CN1259912C (zh) | 2006-06-21 |
Family
ID=89980266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB038012936A Expired - Fee Related CN1259912C (zh) | 2002-03-14 | 2003-03-13 | 用于治疗升高的血压的西酞普兰 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7141604B2 (zh) |
| EP (1) | EP1490049B1 (zh) |
| JP (1) | JP2005519945A (zh) |
| KR (1) | KR100718368B1 (zh) |
| CN (1) | CN1259912C (zh) |
| AT (1) | ATE324887T1 (zh) |
| AU (1) | AU2003211195B2 (zh) |
| BG (1) | BG108904A (zh) |
| BR (1) | BR0303384A (zh) |
| CA (1) | CA2459834A1 (zh) |
| CY (1) | CY1106129T1 (zh) |
| CZ (1) | CZ2004661A3 (zh) |
| DE (1) | DE60305018T2 (zh) |
| DK (1) | DK1490049T3 (zh) |
| EA (1) | EA008350B1 (zh) |
| EE (1) | EE200400069A (zh) |
| ES (2) | ES2238939B2 (zh) |
| HK (1) | HK1075390A1 (zh) |
| HR (1) | HRP20040165B1 (zh) |
| HU (1) | HU0200980D0 (zh) |
| IL (2) | IL160486A0 (zh) |
| IS (1) | IS2392B (zh) |
| LT (1) | LT5255B (zh) |
| LV (1) | LV13281B (zh) |
| MX (1) | MXPA04008919A (zh) |
| NO (1) | NO20034998D0 (zh) |
| PL (1) | PL368902A1 (zh) |
| PT (1) | PT1490049E (zh) |
| SI (1) | SI1490049T1 (zh) |
| SK (1) | SK2222004A3 (zh) |
| TR (1) | TR200401036T1 (zh) |
| UA (1) | UA77506C2 (zh) |
| WO (1) | WO2003075914A1 (zh) |
| YU (1) | YU91203A (zh) |
| ZA (1) | ZA200408056B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004012763T2 (de) * | 2003-10-10 | 2009-05-07 | Solvay Pharmaceuticals Gmbh | Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker |
| DE102004002638A1 (de) * | 2004-01-19 | 2005-08-18 | Merck Patent Gmbh | Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten |
| EP2008653A1 (de) * | 2007-06-28 | 2008-12-31 | Charité-Universitätsmedizin Berlin | Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1552012A (en) | 1975-12-16 | 1979-09-05 | Du Pont Canada | Process for the treatment of comminuted oats |
| ES2148120T3 (es) * | 1997-07-08 | 2002-01-16 | Lundbeck & Co As H | Metodo para la preparacion de citalopram. |
| EA002770B1 (ru) * | 1997-11-11 | 2002-08-29 | Х.Лундбекк А/С | Способ получения циталопрама |
| US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
-
2002
- 2002-03-14 HU HU0200980A patent/HU0200980D0/hu unknown
-
2003
- 2003-03-13 BR BR0303384-8A patent/BR0303384A/pt not_active IP Right Cessation
- 2003-03-13 YU YU91203A patent/YU91203A/sh unknown
- 2003-03-13 WO PCT/HU2003/000021 patent/WO2003075914A1/en not_active IP Right Cessation
- 2003-03-13 AU AU2003211195A patent/AU2003211195B2/en not_active Ceased
- 2003-03-13 CA CA002459834A patent/CA2459834A1/en not_active Abandoned
- 2003-03-13 KR KR1020047005264A patent/KR100718368B1/ko not_active IP Right Cessation
- 2003-03-13 DE DE60305018T patent/DE60305018T2/de not_active Expired - Fee Related
- 2003-03-13 AT AT03743933T patent/ATE324887T1/de not_active IP Right Cessation
- 2003-03-13 CN CNB038012936A patent/CN1259912C/zh not_active Expired - Fee Related
- 2003-03-13 SK SK222-2004A patent/SK2222004A3/sk unknown
- 2003-03-13 JP JP2003574189A patent/JP2005519945A/ja active Pending
- 2003-03-13 DK DK03743933T patent/DK1490049T3/da active
- 2003-03-13 PL PL03368902A patent/PL368902A1/xx not_active Application Discontinuation
- 2003-03-13 EP EP03743933A patent/EP1490049B1/en not_active Expired - Lifetime
- 2003-03-13 ES ES200450048A patent/ES2238939B2/es not_active Expired - Fee Related
- 2003-03-13 TR TR2004/01036T patent/TR200401036T1/xx unknown
- 2003-03-13 EE EEP200400069A patent/EE200400069A/xx unknown
- 2003-03-13 ES ES03743933T patent/ES2263009T3/es not_active Expired - Lifetime
- 2003-03-13 UA UA20041008333A patent/UA77506C2/uk unknown
- 2003-03-13 IL IL16048603A patent/IL160486A0/xx not_active IP Right Cessation
- 2003-03-13 PT PT03743933T patent/PT1490049E/pt unknown
- 2003-03-13 US US10/489,179 patent/US7141604B2/en not_active Expired - Lifetime
- 2003-03-13 MX MXPA04008919A patent/MXPA04008919A/es active IP Right Grant
- 2003-03-13 EA EA200401147A patent/EA008350B1/ru not_active IP Right Cessation
- 2003-03-13 SI SI200330354T patent/SI1490049T1/sl unknown
- 2003-03-13 CZ CZ2004661A patent/CZ2004661A3/cs unknown
- 2003-11-10 NO NO20034998A patent/NO20034998D0/no not_active Application Discontinuation
-
2004
- 2004-02-19 HR HR20040165A patent/HRP20040165B1/xx not_active IP Right Cessation
- 2004-02-19 IL IL160486A patent/IL160486A/en unknown
- 2004-05-12 LT LT2004049A patent/LT5255B/lt not_active IP Right Cessation
- 2004-08-20 IS IS7418A patent/IS2392B/is unknown
- 2004-10-06 ZA ZA200408056A patent/ZA200408056B/en unknown
- 2004-10-14 BG BG108904A patent/BG108904A/en unknown
- 2004-10-14 LV LVP-04-124A patent/LV13281B/en unknown
-
2005
- 2005-06-29 HK HK05105529A patent/HK1075390A1/xx not_active IP Right Cessation
-
2006
- 2006-07-20 CY CY20061101010T patent/CY1106129T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1084618C (zh) | 5－羟色胺拮抗剂的新应用 | |
| CN1213965A (zh) | 抗心律失常化合物在预防心肌梗塞后死亡中的应用 | |
| RU2501796C2 (ru) | Производные 1,3-дигидроимидазол-2-тиона в качестве ингибиторов дофамин-бета-гидроксилазы | |
| CN1245963C (zh) | 包括心动徐缓剂的药物组合物及其用途 | |
| JP2005519073A (ja) | 睡眠標的モジュレーターを使用する睡眠障害の治療 | |
| CN1259912C (zh) | 用于治疗升高的血压的西酞普兰 | |
| CN1422161A (zh) | 新的β阻断剂与降胆固醇剂的组合物 | |
| CN1857726A (zh) | 一种治疗高血压合并高血脂心脑血管疾病的药物组合物 | |
| CN1298389C (zh) | 一种含替米沙坦和钙离子拮抗剂的复方降压制剂及其应用 | |
| CN1237966C (zh) | 一种复方降压制剂 | |
| CN1809574A (zh) | 喹啉3－氨基苯并二氢吡喃衍生物 | |
| CN1844120A (zh) | 芳基哌嗪修饰的苯并[b]噻酚化合物及制备方法和应用 | |
| TW200846002A (en) | Novel prophylactic and/or therapeutic agent for diabetic neuropathy | |
| CN101062039A (zh) | 治疗神经系统疾病的药物组合物 | |
| CN1237971C (zh) | 含血管紧张素转换酶抑制剂、钙离子拮抗剂和艾司唑仑的复方降压制剂 | |
| CN1052674A (zh) | 新的杂环化合物 | |
| CN1708308A (zh) | 福辛普利降低透析患者心血管事件的用途 | |
| CN1524523A (zh) | 含吲哒帕胺、血管紧张素转换酶抑制剂和螺内酯的复方降压制剂 | |
| CN1823767A (zh) | 一种用于治疗心血管疾病的药物组合物 | |
| WO2003080050A1 (en) | The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl]-6-chloro-1h-indole or its enantiomers for the treatment of diseases and disorders responsive to 5-ht (serotonin) re-uptake inhibition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060621 |